Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer
Treatment of lung cancer with conventional therapies, which include radiation, surgery, and chemotherapy results in multiple undesirable adverse or side effects. The major clinical challenge in developing new drug therapies for lung cancer is resistance, which involves mutations and disturbance in various signaling pathways. Molecular abnormalities related to epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) Kirsten rat sarcoma virus (KRAS) mutations, translocation of the anaplastic lymphoma kinase (ALK) gene, mesenchymal-epithelial transition factor (MET) amplification have been studied to overcome the resistance and to develop new therapies for non-small cell lung cancer (NSCLC). But, inevitable development of resistance presents limits the clinical benefits of various new drugs. Here, we review current progress in the development of molecularly targeted therapies, concerning six clinical biomarkers: EGFR, ALK, MET, ROS-1, KRAS, and B-RAF for NSCLC treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer - 42(2023), 1 vom: 03., Seite 27-50 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rohilla, Suman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EC 2.7.10.1 |
|---|
| Anmerkungen: |
Date Completed 07.02.2023 Date Revised 07.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1615/JEnvironPatholToxicolOncol.2022042983 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352450169 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352450169 | ||
| 003 | DE-627 | ||
| 005 | 20231226053743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1615/JEnvironPatholToxicolOncol.2022042983 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352450169 | ||
| 035 | |a (NLM)36734951 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rohilla, Suman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Developments and Challenges in Molecular-Targeted Therapy of Non-Small-Cell Lung Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.02.2023 | ||
| 500 | |a Date Revised 07.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Treatment of lung cancer with conventional therapies, which include radiation, surgery, and chemotherapy results in multiple undesirable adverse or side effects. The major clinical challenge in developing new drug therapies for lung cancer is resistance, which involves mutations and disturbance in various signaling pathways. Molecular abnormalities related to epidermal growth factor receptor (EGFR), v-Raf murine sarcoma viral oncogene homolog B1 (B-RAF) Kirsten rat sarcoma virus (KRAS) mutations, translocation of the anaplastic lymphoma kinase (ALK) gene, mesenchymal-epithelial transition factor (MET) amplification have been studied to overcome the resistance and to develop new therapies for non-small cell lung cancer (NSCLC). But, inevitable development of resistance presents limits the clinical benefits of various new drugs. Here, we review current progress in the development of molecularly targeted therapies, concerning six clinical biomarkers: EGFR, ALK, MET, ROS-1, KRAS, and B-RAF for NSCLC treatment | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Singh, Mahaveer |e verfasserin |4 aut | |
| 700 | 1 | |a Alzarea, Sami I |e verfasserin |4 aut | |
| 700 | 1 | |a Almalki, Waleed Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Abbasi, Fahad A |e verfasserin |4 aut | |
| 700 | 1 | |a Kazmi, Imran |e verfasserin |4 aut | |
| 700 | 1 | |a Afzal, Obaid |e verfasserin |4 aut | |
| 700 | 1 | |a Altamimi, Abdulmalik Saleh Alfawaz |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sachin Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Chellappan, Dinesh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Dua, Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Gaurav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer |d 1985 |g 42(2023), 1 vom: 03., Seite 27-50 |w (DE-627)NLM013157728 |x 2162-6537 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:1 |g day:03 |g pages:27-50 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1615/JEnvironPatholToxicolOncol.2022042983 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 1 |b 03 |h 27-50 | ||